|
PART 1 MOLECULAR BIOLOGY OF CANCER |
|
|
|
Molecular Methods in Oncology |
|
|
3 | (48) |
|
|
|
3 | (5) |
|
|
|
Improved Analysis of Mutations in Oncogenes and Tumor Suppressor Genes |
|
|
3 | (1) |
|
Highly Parallelized Single-Nucleotide Polymorphism Assays Can Also Be Used for Somatic Genotyping |
|
|
4 | (1) |
|
Increasing the Accuracy of Sequence Information Derived from Polymerase Chain Reaction Amplification |
|
|
5 | (1) |
|
Multiplex Real-Time Polymerase Chain Reaction Amplification for Detection of Minimal Residual Disease or Viral Load |
|
|
5 | (1) |
|
Mutation Detection Using In Situ Hybridization Methods Coupled with DNA Amplification |
|
|
5 | (1) |
|
High-Throughput Methods for Measuring Gene Dosage Alterations |
|
|
6 | (1) |
|
Whole Genome Amplification of Microdissected Tissue |
|
|
6 | (1) |
|
Amplification of Genomic Representations for Analysis of Gene Gain/Loss |
|
|
6 | (1) |
|
Tumor Classification Using Real-Time Polymerase Chain Reaction to Measure Messenger RNA Levels |
|
|
6 | (1) |
|
Biomarker Detection Using DNA-Amplified Immunoassays |
|
|
7 | (1) |
|
Amplification-Based Approaches for DNA Methylation Analysis in Cancer |
|
|
7 | (1) |
|
|
|
8 | (5) |
|
|
|
Biochemistry and Function |
|
|
8 | (2) |
|
RNA Interference in Mammals |
|
|
10 | (1) |
|
|
|
11 | (2) |
|
|
|
13 | (13) |
|
|
|
|
|
|
|
DNA Microarrays and the Molecular Profiling of Human Cancers |
|
|
13 | (1) |
|
|
|
13 | (2) |
|
Pediatric Acute Lymphoblastic Leukemia |
|
|
15 | (3) |
|
Diffuse Large B-Cell Lymphoma |
|
|
18 | (1) |
|
|
|
19 | (2) |
|
Microarrays, Tumor Aggressiveness, and Metastasis |
|
|
21 | (1) |
|
Are DNA Microarrays Ready for Routine Clinical Management of Patients with Cancer? |
|
|
22 | (2) |
|
|
|
24 | (2) |
|
|
|
26 | (8) |
|
|
|
|
|
Tissue Microarray Construction |
|
|
26 | (2) |
|
Tissue Microarray Visualization |
|
|
28 | (1) |
|
Tissue Microarray Analysis |
|
|
29 | (3) |
|
Tissue Microarray Applications |
|
|
32 | (2) |
|
|
|
34 | (9) |
|
|
|
|
|
Chromosome Structure and Function |
|
|
34 | (2) |
|
|
|
36 | (2) |
|
Chromosome Abnormalities in Cancer |
|
|
38 | (4) |
|
Data Mining in Cancer Cytogenetics |
|
|
42 | (1) |
|
|
|
43 | (8) |
|
|
|
``Flavors'' of Bioinformatics |
|
|
44 | (1) |
|
|
|
44 | (1) |
|
Electronic Information Provisioning |
|
|
44 | (2) |
|
In Silico Biomedical Applications |
|
|
46 | (4) |
|
|
|
50 | (1) |
|
|
|
51 | (22) |
|
|
|
|
|
|
|
Understanding Cancer at the Molecular Level: An Evolving Frontier |
|
|
51 | (1) |
|
Genetic Mechanisms of Cancer Progression |
|
|
51 | (6) |
|
Postgenome Challenge for Molecular Medicine |
|
|
57 | (1) |
|
Tissue Microdissection Technology Brings Molecular Analysis to the Tissue Level |
|
|
58 | (1) |
|
Complementary DNA Microarrays As a Tool to Analyze Gene Expression Patterns in Human Cancer |
|
|
59 | (4) |
|
Beyond Functional Genomics to Cancer Proteomics |
|
|
63 | (1) |
|
Molecular Diagnostics and Individualized Cancer Therapy |
|
|
63 | (4) |
|
|
|
67 | (6) |
|
Molecular Targets in Oncology |
|
|
73 | (40) |
|
Signal Transduction Systems |
|
|
73 | (10) |
|
|
|
|
|
Sensory Machinery: Ligands and Receptors |
|
|
73 | (3) |
|
Propagation of Signals to the Cell Interior |
|
|
76 | (4) |
|
Efficiency and Specificity: Formation of Multiprotein Signaling Complexes |
|
|
80 | (1) |
|
Regulation of Protein Levels: Transcription, Translation, and Proteolysis |
|
|
81 | (2) |
|
|
|
83 | (12) |
|
|
|
|
|
83 | (4) |
|
Regulation of the Cell Cycle |
|
|
87 | (3) |
|
|
|
90 | (3) |
|
Cell Cycle As a Target for Therapy |
|
|
93 | (1) |
|
|
|
94 | (1) |
|
|
|
95 | (10) |
|
|
|
|
|
|
|
95 | (1) |
|
|
|
95 | (3) |
|
Critical Role of Apoptosis in Tissue Homeostasis |
|
|
98 | (1) |
|
|
|
99 | (1) |
|
|
|
99 | (1) |
|
|
|
99 | (2) |
|
|
|
101 | (1) |
|
Role of Intracellular Organelles: Mitochondria and Endoplasmic Reticulum |
|
|
101 | (1) |
|
Cell Proliferation and Apoptosis |
|
|
101 | (1) |
|
Possibilities for Therapeutic Intervention |
|
|
102 | (1) |
|
|
|
102 | (3) |
|
|
|
105 | (8) |
|
|
|
|
|
|
|
105 | (1) |
|
Telomerase Structure, Regulation, and Function |
|
|
106 | (1) |
|
Crisis, Telomerase Reactivation, and Alternative Lengthening of Telomeres |
|
|
106 | (1) |
|
Telomere Maintenance and Cancer |
|
|
107 | (1) |
|
|
|
107 | (1) |
|
Telomere Dynamics, Inflammatory Diseases, and Cancer |
|
|
108 | (1) |
|
Telomere Status as a Biomarker for Cancer |
|
|
109 | (1) |
|
Telomerase and Telomere Maintenance As Therapeutic Targets |
|
|
109 | (2) |
|
Rational Clinical Trial Designs of Telomere- and Telomerase-Based Therapeutics |
|
|
111 | (2) |
|
|
|
113 | (16) |
|
William G. Stetler-Stevenson |
|
|
Tumor Progression and Genetic Instability |
|
|
113 | (1) |
|
Origins of Metastatic Tumor Cells |
|
|
114 | (1) |
|
Microarray Analysis of Tumor Progression and Metastasis |
|
|
115 | (1) |
|
Tumorigenesis and Metastasis Are Under Separate Genetic Control: Tumor Suppressor Genes |
|
|
116 | (1) |
|
|
|
117 | (1) |
|
Tumor Microenvironment: Determinant of Metastatic Potential and Site of Metastasis |
|
|
118 | (1) |
|
|
|
119 | (1) |
|
Tumor Invasion of the Basement Membrane |
|
|
119 | (1) |
|
Initiation of Cell Migration |
|
|
119 | (1) |
|
Cell-Cell Adhesion: Metastasis Suppressor |
|
|
120 | (1) |
|
Cell Matrix Interactions and Tumor Cell Migration |
|
|
121 | (1) |
|
Role of CD44 in Tumor Invasion and Metastasis |
|
|
121 | (1) |
|
Role of Integrins in Tumor Progression |
|
|
122 | (2) |
|
|
|
124 | (1) |
|
Proteases in Tumor Cell Invasion |
|
|
125 | (1) |
|
|
|
126 | (3) |
|
|
|
129 | (10) |
|
|
|
|
|
|
|
|
|
|
|
129 | (2) |
|
Phenotypic Diversity of Organ-Specific Endothelial Cells |
|
|
131 | (1) |
|
|
|
132 | (1) |
|
Host-Mediated Angiogenesis |
|
|
132 | (1) |
|
Overview of Antiangiogenic and Antivascular Therapies |
|
|
133 | (1) |
|
Antivascular Therapy for Bone Metastasis |
|
|
134 | (1) |
|
Clinical Studies of Imatinib |
|
|
135 | (1) |
|
Discrepancy between Results of Preclinical and Clinical Trials |
|
|
135 | (1) |
|
Basic Principles for Design of Clinical Trials of Antiangiogenic Agents |
|
|
135 | (1) |
|
|
|
136 | (3) |
|
|
|
139 | (26) |
|
|
|
|
|
|
|
140 | (1) |
|
Biologic Sources of Tumor-Associated Antigens |
|
|
140 | (1) |
|
Presentation of Tumor Antigens to T Cells |
|
|
141 | (5) |
|
Role of Antigen-Presenting Cells in Activating Antitumor T Cells |
|
|
146 | (2) |
|
T-Cell Recognition of Tumor Antigens |
|
|
148 | (1) |
|
Maturation of Antitumor T Cells |
|
|
149 | (1) |
|
Activation of Mature Antitumor T Cells |
|
|
150 | (4) |
|
Activation States of Antitumor T Cells |
|
|
154 | (1) |
|
Functions of Mature Antitumor T Cells |
|
|
155 | (2) |
|
|
|
157 | (8) |
|
PART 2 PRINCIPLES OF ONCOLOGY |
|
|
|
Etiology of Cancer: Viruses |
|
|
165 | (20) |
|
|
|
165 | (8) |
|
Gary L. Buchschacher, Jr. |
|
|
|
|
Retroviruses: Background, Replication Cycle, and Molecular Genetics |
|
|
165 | (1) |
|
Mechanisms of Retroviral Oncogenesis |
|
|
166 | (2) |
|
Human T-Lymphotropic Virus Type 1 |
|
|
168 | (1) |
|
Human T-Lymphotropic Virus Type 2 |
|
|
169 | (1) |
|
Human Immunodeficiency Virus |
|
|
169 | (2) |
|
|
|
171 | (2) |
|
|
|
173 | (12) |
|
|
|
|
|
Hepadnaviruses and Hepatocellular Carcinoma |
|
|
174 | (1) |
|
Papillomaviruses and Human Cancer |
|
|
175 | (5) |
|
|
|
180 | (1) |
|
Kaposi's Sarcoma-Associated Herpesvirus |
|
|
181 | (2) |
|
Simian Vacuolating Virus 40 and the Human Polyomaviruses |
|
|
183 | (2) |
|
Etiology of Cancer: Chemical Factors |
|
|
185 | (8) |
|
|
|
|
|
Nature of Chemical Carcinogens: Chemistry and Metabolism |
|
|
185 | (1) |
|
Animal Model Systems and Chemical Carcinogenesis |
|
|
186 | (1) |
|
DNA Repair Protects the Host from Chemical Carcinogens |
|
|
187 | (1) |
|
Genetic Susceptibility to Chemical Carcinogenesis |
|
|
187 | (1) |
|
Determination of Chemical Carcinogens for Humans and Population-Based Risk Assessment |
|
|
187 | (1) |
|
Chemical Carcinogenesis and Cancer Risk |
|
|
187 | (2) |
|
Tumor Suppressor Genes in Human Cancer |
|
|
189 | (1) |
|
Tobacco Smoking and Cancer Risk |
|
|
190 | (3) |
|
Etiology of Cancer: Tobacco Use |
|
|
193 | (8) |
|
|
|
|
|
Effects of Tobacco Use and Cessation on Cancer Risk |
|
|
193 | (3) |
|
Effect of Tobacco Use on Cardiovascular Disease |
|
|
196 | (1) |
|
Cigars, Pipes, and Smokeless Tobacco |
|
|
196 | (1) |
|
|
|
197 | (1) |
|
National Trends in Smoking Prevalence |
|
|
197 | (1) |
|
Disparities in Active Tobacco Use and Cessation |
|
|
197 | (1) |
|
Cigarette Product Modification---Harm Reduction |
|
|
198 | (1) |
|
Tobacco and Nicotine Addiction |
|
|
198 | (1) |
|
|
|
198 | (1) |
|
Strategies for Tobacco Control |
|
|
198 | (1) |
|
|
|
198 | (3) |
|
Etiology of Cancer: Physical Factors |
|
|
201 | (16) |
|
|
|
Interactions of Radiation with Cells and Tissues |
|
|
202 | (9) |
|
|
|
211 | (2) |
|
|
|
213 | (4) |
|
|
|
217 | (26) |
|
|
|
217 | (9) |
|
|
|
|
|
|
|
218 | (1) |
|
|
|
219 | (3) |
|
Interpretation of Epidemiologic Findings |
|
|
222 | (1) |
|
Special Topic: Molecular and Genetic Epidemiology |
|
|
223 | (3) |
|
|
|
226 | (17) |
|
|
|
|
|
|
|
Measures of the Cancer Burden |
|
|
226 | (4) |
|
Data Sources and Age Standardization |
|
|
230 | (1) |
|
|
|
231 | (3) |
|
Demographic and Geographic Patterns |
|
|
234 | (4) |
|
Issues in the Interpretation and Understanding of Temporal Trends |
|
|
238 | (2) |
|
|
|
240 | (3) |
|
Principles of Surgical Oncology |
|
|
243 | (24) |
|
|
|
243 | (10) |
|
|
|
|
|
243 | (1) |
|
Anesthesia for Oncologic Surgery |
|
|
244 | (2) |
|
Determination of Operative Risk |
|
|
246 | (3) |
|
|
|
249 | (2) |
|
|
|
251 | (2) |
|
|
|
253 | (14) |
|
|
|
|
|
Physiology of Laparoscopy |
|
|
253 | (2) |
|
|
|
255 | (2) |
|
Laparoscopy in the Diagnosis of Malignancy |
|
|
257 | (1) |
|
Laparoscopy in the Staging of Malignancy |
|
|
258 | (5) |
|
Laparoscopy in the Treatment of Malignancy |
|
|
263 | (2) |
|
Laparoscopy in the Palliation of Malignancy |
|
|
265 | (1) |
|
|
|
265 | (2) |
|
Principles of Radiation Oncology |
|
|
267 | (28) |
|
|
|
|
|
|
|
Biologic Aspects of Radiation Oncology |
|
|
267 | (9) |
|
Physical Aspects of Radiation Oncology |
|
|
276 | (9) |
|
Clinical Aspects of Radiation Oncology |
|
|
285 | (10) |
|
Principles of Medical Oncology |
|
|
295 | (12) |
|
|
|
|
|
|
|
295 | (1) |
|
Clinical Application of Chemotherapy |
|
|
296 | (1) |
|
Clinical End Points in Evaluating Response to Chemotherapy |
|
|
297 | (1) |
|
Cancer Cell Kinetics and Response to Chemotherapy |
|
|
298 | (1) |
|
Principles Governing the Use of Chemotherapy |
|
|
298 | (2) |
|
Concept of Dose Intensity |
|
|
300 | (1) |
|
Apoptosis, Cell-Cycle Control, and Resistance to Chemotherapy |
|
|
301 | (6) |
|
Pharmacology of Cancer Chemotherapy |
|
|
307 | (116) |
|
|
|
307 | (10) |
|
|
|
|
|
307 | (2) |
|
|
|
309 | (2) |
|
|
|
311 | (1) |
|
Molecularly Targeted Screening |
|
|
312 | (1) |
|
|
|
313 | (1) |
|
|
|
314 | (1) |
|
|
|
315 | (1) |
|
|
|
315 | (1) |
|
|
|
316 | (1) |
|
|
|
317 | (10) |
|
|
|
|
|
317 | (2) |
|
|
|
319 | (4) |
|
|
|
323 | (1) |
|
Special Topics in Pharmacokinetics and Pharmacodynamics |
|
|
324 | (1) |
|
Pharmacokinetics and Pharmacodynamics in Oncology Drug Development |
|
|
325 | (1) |
|
|
|
326 | (1) |
|
|
|
327 | (5) |
|
|
|
|
|
Pharmacogenomics of Chemotherapy Drug Toxicity |
|
|
327 | (3) |
|
Pharmacogenomics of Tumor Response |
|
|
330 | (1) |
|
|
|
331 | (1) |
|
|
|
332 | (12) |
|
|
|
|
|
History of the Alkylating Agents |
|
|
332 | (1) |
|
Chemistry and Cytotoxicity of Alkylating Agents |
|
|
332 | (1) |
|
Classes of Alkylating Agents and Their Properties |
|
|
332 | (6) |
|
Mechanisms of Toxicity and Drug Resistance |
|
|
338 | (2) |
|
Common Toxicities of Alkylating Agents |
|
|
340 | (4) |
|
Cisplatin and Its Analogues |
|
|
344 | (14) |
|
|
|
|
|
|
|
344 | (1) |
|
|
|
345 | (1) |
|
|
|
345 | (2) |
|
|
|
347 | (2) |
|
|
|
349 | (3) |
|
|
|
352 | (2) |
|
Formulation and Administration |
|
|
354 | (1) |
|
|
|
354 | (4) |
|
|
|
358 | (17) |
|
|
|
|
|
|
|
|
|
358 | (3) |
|
|
|
361 | (14) |
|
Topoisomerase Interactive Agents |
|
|
375 | (15) |
|
|
|
|
|
375 | (2) |
|
Mechanism of Action of Topoisomerase Interactive Agents |
|
|
377 | (1) |
|
|
|
377 | (4) |
|
|
|
381 | (3) |
|
Anthracyclines and Related Compounds |
|
|
384 | (4) |
|
Other Topoisomerase Interactive Agents |
|
|
388 | (1) |
|
Secondary Malignancies and Topoisomerase Targeting Therapies |
|
|
389 | (1) |
|
|
|
390 | (26) |
|
|
|
|
|
|
|
390 | (2) |
|
|
|
392 | (6) |
|
|
|
398 | (9) |
|
|
|
407 | (3) |
|
Novel Compounds Targeting Microtubules |
|
|
410 | (1) |
|
Novel Compounds Targeting Mitotic Motor Proteins |
|
|
411 | (5) |
|
Miscellaneous Chemotherapeutic Agents |
|
|
416 | (7) |
|
|
|
|
|
|
|
|
|
416 | (1) |
|
|
|
417 | (1) |
|
|
|
417 | (1) |
|
|
|
418 | (2) |
|
|
|
420 | (3) |
|
Pharmacology of Cancer Biotherapeutics |
|
|
423 | (34) |
|
|
|
423 | (8) |
|
|
|
|
|
|
|
423 | (1) |
|
Biologic Effects of Interferons |
|
|
424 | (2) |
|
Clinical Toxicity of Interferon Administration |
|
|
426 | (1) |
|
Potential Drug Interactions |
|
|
427 | (1) |
|
Oncologic Applications of Interferons |
|
|
427 | (2) |
|
|
|
429 | (2) |
|
|
|
431 | (8) |
|
|
|
|
|
Isolation, Characterization, and Cloning of Interleukin-2 |
|
|
431 | (1) |
|
|
|
431 | (1) |
|
Interleukin-2--Activated Signaling Pathways |
|
|
431 | (1) |
|
In Vitro Effects of Interleukin-2 |
|
|
432 | (1) |
|
Preclinical Studies with Interleukin-2 in Tumor-Bearing Mice |
|
|
432 | (1) |
|
Clinical Applications of Interleukin-2 |
|
|
432 | (5) |
|
|
|
437 | (2) |
|
Histone Deacetylase Inhibitors: New Targeted Anticancer Drugs |
|
|
439 | (6) |
|
|
|
|
|
|
|
|
|
|
|
439 | (1) |
|
Histone Deacetylases and Histone Acetyl Transferases |
|
|
439 | (1) |
|
Histone Acetyltransferases and Histone Deacetylase Inhibitors and Human Cancers |
|
|
439 | (2) |
|
Histone Deacetylase Inhibitors |
|
|
441 | (1) |
|
Activity of Histone Deacetylase Inhibitors |
|
|
441 | (2) |
|
Clinical Trials with Histone Deacetylase Inhibitors |
|
|
443 | (1) |
|
Conclusion and Perspectives |
|
|
444 | (1) |
|
|
|
445 | (12) |
|
|
|
|
|
|
|
|
|
|
|
446 | (1) |
|
Factors Regulating Antibody-Based Tumor Targeting |
|
|
447 | (1) |
|
|
|
448 | (3) |
|
|
|
451 | (2) |
|
Pretargeted Antibody Conjugates |
|
|
453 | (1) |
|
Unconjugated Antibodies with Clinical Activity in Solid Tumors |
|
|
453 | (1) |
|
|
|
454 | (3) |
|
Pharmacology of Endocrine Manipulation |
|
|
457 | (14) |
|
|
|
|
|
|
|
Selective Estrogen Receptor Modulators |
|
|
457 | (4) |
|
Medroxyprogesterone and Megestrol |
|
|
461 | (1) |
|
|
|
462 | (2) |
|
Gonadotropin-Releasing Hormone Analogues |
|
|
464 | (1) |
|
|
|
464 | (1) |
|
|
|
465 | (1) |
|
Diethylstilbestrol and Estradiol (Estrace) |
|
|
465 | (1) |
|
|
|
466 | (5) |
|
Design and Analysis of Clinical Trials |
|
|
471 | (22) |
|
|
|
|
|
471 | (2) |
|
|
|
473 | (5) |
|
Design of Phase III Clinical Trials |
|
|
478 | (5) |
|
Analysis of Phase III Clinical Trials |
|
|
483 | (10) |
|
PART 3 PRACTICE OF ONCOLOGY |
|
|
|
Cancer Prevention: Preventing Tobacco-Related Cancers |
|
|
493 | (14) |
|
|
|
|
|
Tobacco and Nicotine Addiction |
|
|
493 | (1) |
|
|
|
493 | (1) |
|
|
|
494 | (1) |
|
|
|
494 | (1) |
|
Children, Adolescents, and College Students |
|
|
495 | (1) |
|
Cigarette Product Modification |
|
|
495 | (1) |
|
|
|
496 | (1) |
|
|
|
496 | (1) |
|
Environmental Tobacco Smoke |
|
|
496 | (1) |
|
Tobacco Industry Advertising Strategies |
|
|
497 | (1) |
|
Strategies for Tobacco Control |
|
|
498 | (1) |
|
|
|
498 | (1) |
|
|
|
498 | (1) |
|
Nicotine Replacement Therapy |
|
|
499 | (1) |
|
|
|
500 | (1) |
|
National Action Plan for Tobacco Cessation |
|
|
500 | (1) |
|
Tobacco Restrictions at the Policy Level |
|
|
500 | (1) |
|
Tobacco Taxes that Fund Dedicated, Comprehensive Statewide Tobacco Control Programs |
|
|
500 | (1) |
|
Mass Media and Counter-Advertising |
|
|
501 | (1) |
|
Tobacco Litigation, Tobacco Settlement, and International Treaties |
|
|
502 | (1) |
|
Proposed U.S. Food and Drug Administration Regulations |
|
|
502 | (1) |
|
|
|
503 | (4) |
|
Cancer Prevention: Diet and Chemopreventive Agents |
|
|
507 | (48) |
|
|
|
507 | (7) |
|
|
|
|
|
508 | (1) |
|
|
|
509 | (1) |
|
|
|
510 | (1) |
|
|
|
511 | (1) |
|
|
|
511 | (3) |
|
|
|
514 | (4) |
|
|
|
|
|
514 | (1) |
|
Properties of Dietary Fiber |
|
|
514 | (1) |
|
Observational Studies and Clinical Trials |
|
|
514 | (1) |
|
|
|
515 | (1) |
|
Calculation of Fiber Intake |
|
|
515 | (1) |
|
Dietary Fiber and Colorectal Cancer |
|
|
515 | (1) |
|
Fiber Intake and Colorectal Adenomas |
|
|
516 | (1) |
|
Fiber Intake and Breast Cancer |
|
|
516 | (1) |
|
Dietary Fiber and Stomach Cancer |
|
|
516 | (1) |
|
|
|
517 | (1) |
|
|
|
517 | (1) |
|
Fruit and Vegetable Consumption |
|
|
518 | (3) |
|
|
|
|
|
518 | (1) |
|
Diet Assessment Instruments |
|
|
518 | (1) |
|
|
|
518 | (1) |
|
Fruit and Vegetable Consumption and Colorectal Cancer |
|
|
518 | (1) |
|
Fruit and Vegetable Consumption and Stomach Cancer |
|
|
518 | (1) |
|
Fruit and Vegetable Consumption and Breast Cancer |
|
|
519 | (1) |
|
Fruit and Vegetable Consumption and Lung Cancer |
|
|
519 | (1) |
|
Micronutrient Components of Fruits and Vegetables and Cancer |
|
|
519 | (1) |
|
|
|
520 | (1) |
|
Retinoids, Carotenoids, and Micronutrients |
|
|
521 | (15) |
|
|
|
|
|
|
|
521 | (1) |
|
Retinoid Biology and Pharmacology |
|
|
522 | (1) |
|
Carotenoid Biology and Actions |
|
|
522 | (1) |
|
|
|
523 | (9) |
|
Translational and Intermediate End Point Studies in Retinoid Chemoprevention |
|
|
532 | (1) |
|
Other Retinoids and Carotenoids |
|
|
533 | (1) |
|
|
|
533 | (3) |
|
|
|
536 | (5) |
|
|
|
Naturally Occurring Dietary Carcinogens |
|
|
536 | (2) |
|
Products of Food Preparation and Processing |
|
|
538 | (2) |
|
Synthetic Carcinogens in the Diet |
|
|
540 | (1) |
|
|
|
540 | (1) |
|
Cyclooxygenase Inhibitors |
|
|
541 | (8) |
|
|
|
|
|
Pharmacology of Nonsteroidal Antiinflammatory Drugs |
|
|
541 | (1) |
|
Toxicity of Nonsteroidal Antiinflammatory Drugs |
|
|
542 | (1) |
|
History of the Inflammation Hypothesis |
|
|
542 | (1) |
|
Nonsteroidal Antiinflammatory Drugs in Relation to Other Cancers |
|
|
543 | (1) |
|
Mechanisms of Cancer Inhibition |
|
|
544 | (2) |
|
|
|
546 | (1) |
|
Ongoing Randomized Clinical Trials |
|
|
546 | (1) |
|
Implications for Research and Clinical Practice |
|
|
546 | (2) |
|
|
|
548 | (1) |
|
Physical Activity and Body Weight |
|
|
549 | (6) |
|
|
|
|
|
|
|
549 | (3) |
|
|
|
552 | (1) |
|
|
|
553 | (2) |
|
Cancer Prevention: Role of Surgery in Cancer Prevention |
|
|
555 | (12) |
|
|
|
Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma |
|
|
555 | (1) |
|
Barrett's Esophagus and Esophageal Cancer |
|
|
556 | (2) |
|
Hereditary Diffuse Gastric Cancer |
|
|
558 | (1) |
|
|
|
558 | (3) |
|
|
|
561 | (2) |
|
|
|
563 | (1) |
|
Testicular Cancer and Cryptorchidism |
|
|
564 | (3) |
|
|
|
567 | (14) |
|
|
|
|
|
|
|
What Is Cancer Screening? |
|
|
567 | (1) |
|
Evaluation of a Screening Test |
|
|
568 | (1) |
|
|
|
569 | (3) |
|
Cervical Cancer Screening |
|
|
572 | (1) |
|
Colorectal Cancer Screening |
|
|
573 | (1) |
|
|
|
574 | (1) |
|
Prostate Cancer Screening |
|
|
574 | (2) |
|
|
|
576 | (1) |
|
Adherence to Cancer Screening |
|
|
577 | (1) |
|
|
|
577 | (4) |
|
Advanced Molecular Diagnostics |
|
|
581 | (8) |
|
|
|
|
|
Present Impact of Novel Technologies on Clinical Practice |
|
|
582 | (2) |
|
|
|
584 | (2) |
|
|
|
586 | (3) |
|
|
|
589 | (48) |
|
Functional and Metabolic Imaging |
|
|
589 | (28) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
589 | (5) |
|
Therapeutic Response Assessment |
|
|
594 | (1) |
|
Brain and Head/Neck Cancers |
|
|
595 | (2) |
|
|
|
597 | (3) |
|
|
|
600 | (1) |
|
|
|
601 | (3) |
|
|
|
604 | (1) |
|
|
|
605 | (2) |
|
|
|
607 | (1) |
|
|
|
607 | (1) |
|
|
|
608 | (1) |
|
|
|
609 | (1) |
|
|
|
610 | (1) |
|
Molecular Imaging in Oncology |
|
|
611 | (6) |
|
|
|
617 | (20) |
|
|
|
|
|
|
|
617 | (2) |
|
|
|
619 | (1) |
|
Gastrointestinal Procedures |
|
|
619 | (1) |
|
|
|
620 | (3) |
|
|
|
623 | (3) |
|
|
|
626 | (3) |
|
Inferior Vena Cava Filters |
|
|
629 | (1) |
|
|
|
630 | (1) |
|
|
|
631 | (1) |
|
Embolotherapy for Hepatic Neoplasms |
|
|
631 | (1) |
|
|
|
632 | (2) |
|
Emerging Therapies and Future Directions |
|
|
634 | (3) |
|
Cancer Diagnosis: Endoscopy |
|
|
637 | (16) |
|
Gastrointestinal Endoscopy |
|
|
637 | (6) |
|
|
|
|
|
637 | (3) |
|
|
|
640 | (1) |
|
Endoscopic Ultrasonography |
|
|
641 | (1) |
|
Small Bowel Endoscopy and Capsule Endoscopy |
|
|
641 | (1) |
|
Endoscopic Retrograde Cholangiopancreatography |
|
|
642 | (1) |
|
|
|
643 | (10) |
|
|
|
|
|
|
|
|
|
643 | (2) |
|
|
|
645 | (2) |
|
Cervical Mediastinoscopy and Anterior Mediastinotomy |
|
|
647 | (1) |
|
Video-Assisted Thoracoscopy |
|
|
648 | (5) |
|
Cancer of the Head and Neck |
|
|
653 | (92) |
|
Molecular Biology of Head and Neck Tumors |
|
|
653 | (9) |
|
|
|
|
|
653 | (1) |
|
|
|
653 | (1) |
|
|
|
654 | (1) |
|
Suppressive Growth Regulation |
|
|
655 | (1) |
|
|
|
655 | (2) |
|
|
|
657 | (1) |
|
|
|
658 | (1) |
|
|
|
658 | (1) |
|
|
|
658 | (4) |
|
Treatment of Head and Neck Cancers |
|
|
662 | (70) |
|
|
|
|
|
|
|
Epidemiology of Head and Neck Cancer |
|
|
662 | (1) |
|
|
|
662 | (1) |
|
|
|
662 | (1) |
|
Natural History and Patterns of Spread of Squamous Cell Carcinoma |
|
|
663 | (2) |
|
|
|
665 | (1) |
|
|
|
665 | (1) |
|
General Principles for Selection of Treatment |
|
|
665 | (1) |
|
|
|
666 | (66) |
|
Rehabilitation after Treatment for Head and Neck Cancer |
|
|
732 | (13) |
|
|
|
|
|
General Functional Consequences of Treatment for Head and Neck Cancer |
|
|
732 | (2) |
|
|
|
734 | (1) |
|
Radiation Therapy Impact on Speech, Voice, and Swallowing Functions |
|
|
735 | (1) |
|
Evaluation of Speech, Voice, and Swallowing after Head and Neck Cancer Treatment |
|
|
736 | (2) |
|
Rehabilitation of Posttreatment Functional Limitations |
|
|
738 | (4) |
|
|
|
742 | (3) |
|
|
|
745 | (100) |
|
Molecular Biology of Lung Cancer |
|
|
745 | (8) |
|
|
|
|
|
|
|
Genetic and Epigenetic Alterations in Lung Cancers |
|
|
745 | (1) |
|
Protooncogenes and Growth Stimulation |
|
|
746 | (2) |
|
Tumor Suppressor Genes and Growth Suppression |
|
|
748 | (1) |
|
Other Biologic Abnormalities for Lung Cancer Development |
|
|
749 | (2) |
|
Molecular Tools in the Lung Cancer Clinic |
|
|
751 | (2) |
|
Non--Small Cell Lung Cancer |
|
|
753 | (57) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
753 | (1) |
|
|
|
753 | (4) |
|
|
|
757 | (4) |
|
|
|
761 | (1) |
|
|
|
762 | (1) |
|
|
|
763 | (3) |
|
Methods to Establish Tissue Diagnosis |
|
|
766 | (2) |
|
|
|
768 | (2) |
|
|
|
770 | (1) |
|
Overview of Invasive Lung Cancer Management: Treatment Modalities |
|
|
770 | (7) |
|
Specifics of Lung Cancer Management |
|
|
777 | (33) |
|
|
|
810 | (35) |
|
|
|
|
|
|
|
Epidemiology and Etiology |
|
|
810 | (1) |
|
|
|
810 | (1) |
|
|
|
811 | (1) |
|
Staging Evaluation and Prognostic Factors |
|
|
812 | (3) |
|
|
|
815 | (1) |
|
|
|
816 | (2) |
|
|
|
818 | (1) |
|
Approach to Patients with Limited Disease |
|
|
819 | (1) |
|
Role of Radiotherapy in Limited Disease |
|
|
820 | (3) |
|
Role of Surgery in Limited Disease |
|
|
823 | (3) |
|
Approach to Patients with Extensive Disease |
|
|
826 | (1) |
|
Strategies to Optimize Chemotherapy Response |
|
|
827 | (3) |
|
Hematopoietic Growth Factors |
|
|
830 | (2) |
|
Management of Small Cell Lung Cancer in the Elderly and Infirm |
|
|
832 | (1) |
|
Biologic Response Modifiers and Other Treatments |
|
|
833 | (1) |
|
|
|
834 | (1) |
|
Treatment Outcome and Long-Term Survival |
|
|
835 | (1) |
|
Extrapulmonary Small Cell Carcinoma |
|
|
836 | (9) |
|
Neoplasms of the Mediastinum |
|
|
845 | (16) |
|
|
|
|
|
|
|
|
|
845 | (1) |
|
|
|
845 | (1) |
|
Diagnostic Considerations |
|
|
846 | (2) |
|
|
|
848 | (4) |
|
|
|
852 | (3) |
|
|
|
855 | (1) |
|
|
|
855 | (3) |
|
Primary Cardiac Malignancies |
|
|
858 | (3) |
|
Cancers of the Gastrointestinal Tract |
|
|
861 | (278) |
|
|
|
861 | (48) |
|
|
|
|
|
|
|
|
|
861 | (1) |
|
Etiologic Factors and Predisposing Conditions |
|
|
862 | (3) |
|
Applied Anatomy and Histology |
|
|
865 | (2) |
|
|
|
867 | (2) |
|
Natural History and Patterns of Failure |
|
|
869 | (1) |
|
|
|
869 | (1) |
|
Diagnostic Studies and Pretreatment Staging |
|
|
870 | (1) |
|
|
|
871 | (1) |
|
|
|
872 | (29) |
|
Stage-Directed Treatment Recommendations |
|
|
901 | (8) |
|
|
|
909 | (36) |
|
|
|
|
|
|
|
|
|
Epidemiology and Etiology |
|
|
909 | (3) |
|
|
|
912 | (2) |
|
Pathology and Tumor Biology |
|
|
914 | (1) |
|
Clinical Presentation and Pretreatment Evaluation |
|
|
915 | (2) |
|
Staging, Classification, and Prognosis |
|
|
917 | (4) |
|
Treatment of Localized Disease |
|
|
921 | (13) |
|
Treatment of Advanced Disease (Stage IV) |
|
|
934 | (11) |
|
|
|
945 | (41) |
|
|
|
|
|
|
|
|
|
Christine A. Iacobuzio-Donohue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Epidemiology and Risk Factors |
|
|
945 | (2) |
|
|
|
947 | (3) |
|
|
|
950 | (2) |
|
Gene Expression Profiling and Beyond |
|
|
952 | (1) |
|
Screening and Early Detection |
|
|
953 | (2) |
|
Clinicopathologic Staging |
|
|
955 | (2) |
|
Clinical Presentation and Evaluation |
|
|
957 | (3) |
|
Treatment of Potentially Resectable Disease |
|
|
960 | (9) |
|
Treatment of Locally Advanced Disease |
|
|
969 | (4) |
|
Treatment of Metastatic and Recurrent Disease |
|
|
973 | (9) |
|
|
|
982 | (4) |
|
|
|
986 | (23) |
|
|
|
|
|
|
|
|
|
987 | (1) |
|
|
|
988 | (3) |
|
|
|
991 | (1) |
|
|
|
991 | (2) |
|
|
|
993 | (1) |
|
|
|
993 | (2) |
|
Screening of High-Risk Populations |
|
|
995 | (1) |
|
|
|
996 | (7) |
|
Treatment of Other Primary Liver Tumors |
|
|
1003 | (1) |
|
Summary: Practical Guide to the Management of Patients with Hepatocellular Carcinoma |
|
|
1004 | (5) |
|
Cancer of the Biliary Tree |
|
|
1009 | (26) |
|
|
|
|
|
|
|
|
|
1009 | (13) |
|
Tumors of the Gallbladder |
|
|
1022 | (9) |
|
New Advances for Treatment of Biliary Tract Cancers |
|
|
1031 | (4) |
|
Cancer of the Small Intestine |
|
|
1035 | (15) |
|
|
|
|
|
1036 | (1) |
|
Pathogenetic Mechanisms in Small Intestinal Carcinogenesis |
|
|
1036 | (1) |
|
Genetic and Environmental Factors That Predispose to Malignancy Arising in the Small Intestine |
|
|
1037 | (1) |
|
Presentation and Diagnosis of Cancers Arising in the Small Intestine |
|
|
1038 | (2) |
|
Adenocarcinoma Arising in the Small Intestine |
|
|
1040 | (2) |
|
Carcinoid Tumors Arising in the Small Intestine |
|
|
1042 | (2) |
|
Lymphoma Arising in the Small Intestine |
|
|
1044 | (2) |
|
Mesenchymal Tumors Arising in the Small Intestine |
|
|
1046 | (4) |
|
Gastrointestinal Stromal Tumors |
|
|
1050 | (11) |
|
|
|
Histopathologic Features and Histogenesis |
|
|
1050 | (2) |
|
|
|
1052 | (2) |
|
Treatment Options and Management Decisions in the Era of Molecularly Targeted Therapies for Gastrointestinal Stromal Tumor |
|
|
1054 | (4) |
|
Special Considerations in Gastrointestinal Stromal Tumor |
|
|
1058 | (1) |
|
New Challenges and Alternative Approaches |
|
|
1059 | (2) |
|
|
|
1061 | (49) |
|
|
|
|
|
|
|
|
|
|
|
1061 | (1) |
|
Etiology: Genetic and Environmental Risk Factors |
|
|
1062 | (1) |
|
Biology of Colorectal Cancer: Clinical and Molecular Genetic Risk Factors |
|
|
1063 | (2) |
|
|
|
1065 | (2) |
|
|
|
1067 | (1) |
|
|
|
1068 | (1) |
|
|
|
1068 | (8) |
|
Approaches to Surgical Resection of Colon Cancer |
|
|
1076 | (4) |
|
Polyps and Stage I Colon Cancer |
|
|
1080 | (1) |
|
Stage II and Stage III Colon Cancer |
|
|
1080 | (9) |
|
Surgical Management of Stage IV Disease |
|
|
1089 | (1) |
|
Management of Unresectable Metastatic Disease |
|
|
1089 | (13) |
|
Management of Synchronous Primary and Metastatic Disease |
|
|
1102 | (1) |
|
Unusual Colorectal Tumors |
|
|
1102 | (8) |
|
|
|
1110 | (15) |
|
|
|
|
|
|
|
|
|
|
|
1110 | (1) |
|
|
|
1111 | (2) |
|
|
|
1113 | (1) |
|
|
|
1113 | (3) |
|
Combined Modality Therapy (Stages II and III) |
|
|
1116 | (3) |
|
|
|
1119 | (1) |
|
Management of Unresectable Primary and Locally Advanced Disease (T4) |
|
|
1120 | (1) |
|
Radiation Therapy Technique |
|
|
1121 | (1) |
|
|
|
1122 | (3) |
|
Cancer of the Anal Region |
|
|
1125 | (14) |
|
|
|
|
|
|
|
|
|
1125 | (1) |
|
|
|
1126 | (1) |
|
|
|
1126 | (1) |
|
Risk Factors and Etiology |
|
|
1126 | (1) |
|
|
|
1127 | (1) |
|
|
|
1128 | (1) |
|
|
|
1129 | (1) |
|
Anal Canal Squamous Cancers |
|
|
1129 | (6) |
|
|
|
1135 | (1) |
|
|
|
1135 | (1) |
|
|
|
1135 | (1) |
|
Special Considerations: Patients with Human Immunodeficiency Virus Infection/Acquired Immunodeficiency Syndrome |
|
|
1136 | (3) |
|
Cancers of the Genitourinary System |
|
|
1139 | (130) |
|
|
|
1139 | (29) |
|
|
|
|
|
|
|
Histologic Types of Renal Carcinoma |
|
|
1139 | (10) |
|
Localized Renal Carcinoma |
|
|
1149 | (2) |
|
Metastatic Renal Carcinoma |
|
|
1151 | (17) |
|
Cancer of the Bladder, Ureter, and Renal Pelvis |
|
|
1168 | (24) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1168 | (1) |
|
Screening and Early Detection |
|
|
1169 | (1) |
|
|
|
1169 | (1) |
|
|
|
1170 | (1) |
|
|
|
1171 | (14) |
|
Cancers of the Ureter and Renal Pelvis |
|
|
1185 | (7) |
|
|
|
1192 | (68) |
|
|
|
|
|
|
|
|
|
|
|
States and State Transitions |
|
|
1192 | (3) |
|
Biologic Characterization and Pathology |
|
|
1195 | (8) |
|
Initial Urologic Evaluation: No Cancer Diagnosis |
|
|
1203 | (6) |
|
|
|
1209 | (13) |
|
|
|
1222 | (8) |
|
|
|
1230 | (1) |
|
|
|
1231 | (10) |
|
Clinical Metastases: Castrate |
|
|
1241 | (9) |
|
|
|
1250 | (10) |
|
Cancer of the Urethra and Penis |
|
|
1260 | (9) |
|
|
|
|
|
Cancer of the Male Urethra |
|
|
1260 | (1) |
|
Carcinoma of the Female Urethra |
|
|
1261 | (1) |
|
|
|
1262 | (7) |
|
|
|
1269 | (26) |
|
|
|
|
|
|
|
|
|
|
|
|
|
1269 | (1) |
|
|
|
1269 | (1) |
|
Initial Presentation and Management |
|
|
1270 | (1) |
|
|
|
1270 | (4) |
|
|
|
1274 | (3) |
|
Management of Clinical Stage I Disease |
|
|
1277 | (4) |
|
Management of Clinical Stage II Disease (Low Tumor Burden) |
|
|
1281 | (1) |
|
Management of Stage II and Stage III Disease (High Tumor Burden) |
|
|
1282 | (4) |
|
Management of Relapse after Chemotherapy and Refractory Disease |
|
|
1286 | (1) |
|
|
|
1287 | (2) |
|
Midline Tumors of Uncertain Histogenesis |
|
|
1289 | (1) |
|
|
|
1289 | (6) |
|
|
|
1295 | (104) |
|
Cancer of the Cervix, Vagina, and Vulva |
|
|
1295 | (46) |
|
|
|
|
|
|
|
|
|
1295 | (25) |
|
|
|
1320 | (6) |
|
|
|
1326 | (15) |
|
Cancers of the Uterine Body |
|
|
1341 | (19) |
|
|
|
|
|
|
|
|
|
1341 | (13) |
|
|
|
1354 | (6) |
|
Gestational Trophoblastic Diseases |
|
|
1360 | (4) |
|
|
|
|
|
|
|
|
|
1360 | (1) |
|
|
|
1361 | (1) |
|
Clinical Diagnosis and Human Chorionic Gonadotropin |
|
|
1361 | (1) |
|
|
|
1362 | (2) |
|
Ovarian Cancer, Peritoneal Carcinoma, and Fallopian Tube Carcinoma |
|
|
1364 | (35) |
|
|
|
|
|
|
|
|
|
1364 | (24) |
|
|
|
1388 | (1) |
|
Primary Peritoneal Carcinoma |
|
|
1389 | (1) |
|
Germ Cell Tumors of the Ovary |
|
|
1390 | (2) |
|
|
|
1392 | (1) |
|
|
|
1393 | (6) |
|
|
|
1399 | (90) |
|
Molecular Biology of Breast Cancer |
|
|
1399 | (16) |
|
|
|
|
|
|
|
|
|
1399 | (3) |
|
Steroid and Growth Factor Pathways of Cellular Regulation |
|
|
1402 | (6) |
|
Cell Cycle and Cell Death |
|
|
1408 | (2) |
|
Process of Malignant Progression |
|
|
1410 | (1) |
|
Implications of Molecular Biology for Tumor Prevention, Early Detection, Prognosis, and Response to Therapy |
|
|
1411 | (4) |
|
Malignant Tumors of the Breast |
|
|
1415 | (63) |
|
|
|
|
|
|
|
|
|
Risk Factors for Breast Cancer |
|
|
1415 | (3) |
|
|
|
1418 | (2) |
|
Pathologic Classification of Tumor Types |
|
|
1420 | (1) |
|
|
|
1421 | (2) |
|
Prognostic and Predictive Factors |
|
|
1423 | (4) |
|
Advising the Woman at High Risk for Breast Cancer |
|
|
1427 | (2) |
|
|
|
1429 | (5) |
|
Lobular Carcinoma In Situ |
|
|
1434 | (1) |
|
|
|
1434 | (1) |
|
Early-Stage Breast Cancer |
|
|
1435 | (15) |
|
Locally Advanced and Inflammatory Breast Cancer |
|
|
1450 | (3) |
|
|
|
1453 | (9) |
|
Breast Cancer and Pregnancy |
|
|
1462 | (2) |
|
|
|
1464 | (1) |
|
|
|
1465 | (1) |
|
|
|
1465 | (1) |
|
|
|
1466 | (1) |
|
Axillary Lymph Node Presentation |
|
|
1466 | (1) |
|
Local and Regional Recurrence |
|
|
1467 | (2) |
|
Breast Cancer in the Elderly |
|
|
1469 | (9) |
|
Rehabilitation after Treatment for Cancer of the Breast |
|
|
1478 | (11) |
|
|
|
|
|
Delayed versus Immediate Reconstruction |
|
|
1478 | (1) |
|
Prosthetic Reconstruction |
|
|
1478 | (1) |
|
Autologous Tissue Reconstruction |
|
|
1479 | (2) |
|
Postmastectomy after Breast Irradiation |
|
|
1481 | (1) |
|
Skin-Sparing Mastectomy with Immediate Reconstruction |
|
|
1481 | (2) |
|
|
|
1483 | (6) |
|
Cancer of the Endocrine System |
|
|
1489 | (92) |
|
Molecular Biology of Endocrine Tumors |
|
|
1489 | (13) |
|
|
|
|
|
Multiple Endocrine Neoplasia Syndromes |
|
|
1489 | (6) |
|
Molecular Pathogenesis of Sporadic Thyroid Neoplasms |
|
|
1495 | (2) |
|
Genetic Abnormalities in Parathyroid Neoplasms |
|
|
1497 | (1) |
|
Other Genetic Loci Implicated in Familial Hypercalcemic Syndromes |
|
|
1498 | (1) |
|
|
|
1499 | (1) |
|
Genetic Abnormalities in Adrenal Neoplasms |
|
|
1499 | (1) |
|
|
|
1500 | (2) |
|
|
|
1502 | (19) |
|
|
|
|
|
Thyroid Tumor Classification and Staging Systems |
|
|
1502 | (1) |
|
Epidemiology and Demographics |
|
|
1503 | (1) |
|
Etiology and Risk Factors |
|
|
1503 | (3) |
|
Evaluation of the Thyroid Nodule |
|
|
1506 | (2) |
|
Well-Differentiated Thyroid Carcinoma |
|
|
1508 | (2) |
|
Treatment of Well-and Intermediately Differentiated Thyroid Carcinoma |
|
|
1510 | (4) |
|
Poorly Differentiated Thyroid Carcinoma |
|
|
1514 | (1) |
|
Medullary Thyroid Carcinoma |
|
|
1515 | (2) |
|
|
|
1517 | (1) |
|
Metastatic Disease of the Thyroid |
|
|
1518 | (1) |
|
Thyroid Carcinoma in Children |
|
|
1518 | (3) |
|
|
|
1521 | (7) |
|
|
|
Primary Hyperparathyroidism |
|
|
1522 | (1) |
|
|
|
1522 | (1) |
|
|
|
1522 | (1) |
|
|
|
1522 | (2) |
|
|
|
1524 | (1) |
|
|
|
1524 | (1) |
|
|
|
1525 | (1) |
|
|
|
1525 | (1) |
|
|
|
1526 | (2) |
|
|
|
1528 | (12) |
|
|
|
Pathology of the Adrenal Cortex |
|
|
1528 | (1) |
|
Clinical Presentations of Adrenal Cortical Neoplasms |
|
|
1529 | (4) |
|
Treatment of Adrenal Cortical Neoplasms |
|
|
1533 | (2) |
|
|
|
1535 | (5) |
|
Pancreatic Endocrine Tumors |
|
|
1540 | (19) |
|
H. Richard Alexander, Jr. |
|
|
|
|
Pathogenesis, Pathology, Tumor Biology |
|
|
1541 | (2) |
|
Clinical Presentation and Diagnosis |
|
|
1543 | (4) |
|
Imaging and Localization of Pancreatic Endocrine Tumors |
|
|
1547 | (1) |
|
Treatment of Resectable Disease |
|
|
1548 | (7) |
|
Treatment of Metastatic Disease |
|
|
1555 | (4) |
|
Carcinoid Tumors and the Carcinoid Syndrome |
|
|
1559 | (16) |
|
|
|
|
|
Pathology and Tumor Histology |
|
|
1559 | (3) |
|
|
|
1562 | (1) |
|
|
|
1562 | (1) |
|
|
|
1563 | (8) |
|
Treatment of the Carcinoid Tumor |
|
|
1571 | (4) |
|
Multiple Endocrine Neoplasias |
|
|
1575 | (6) |
|
|
|
|
|
Multiple Endocrine Neoplasia Type 1 |
|
|
1575 | (3) |
|
Familial Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Types 2A and 2B |
|
|
1578 | (3) |
|
Sarcomas of the Soft Tissues and Bone |
|
|
1581 | (106) |
|
|
|
1581 | (57) |
|
|
|
|
|
|
|
|
|
|
|
1581 | (1) |
|
|
|
1581 | (3) |
|
|
|
1584 | (1) |
|
Pathologic Classification |
|
|
1584 | (3) |
|
|
|
1587 | (1) |
|
|
|
1588 | (1) |
|
Clinicopathologic Features of Specific types of Bengin and Malignant Soft Tissue Tumors |
|
|
1589 | (8) |
|
|
|
1597 | (1) |
|
|
|
1597 | (5) |
|
Management of Extremity and Superficial Truncal Soft Tissue Sarcoma |
|
|
1602 | (1) |
|
|
|
1603 | (5) |
|
|
|
1608 | (1) |
|
|
|
1609 | (1) |
|
|
|
1610 | (1) |
|
|
|
1611 | (5) |
|
Preoperative Chemotherapy |
|
|
1616 | (1) |
|
Intraarterial Chemotherapy |
|
|
1617 | (1) |
|
Hyperthermia and Limb Perfusion |
|
|
1617 | (1) |
|
Special Features of the Management of Sarcomas of Nonextremity Sites |
|
|
1618 | (2) |
|
Serious Complications of Primary Treatment |
|
|
1620 | (2) |
|
|
|
1622 | (1) |
|
Quality of Life and Functional Outcome |
|
|
1623 | (1) |
|
Treatment of Local Recurrence |
|
|
1623 | (1) |
|
Management of Advanced Disease |
|
|
1624 | (1) |
|
Resection of Metastatic Disease |
|
|
1624 | (1) |
|
Systemic Therapy for Advanced Disease |
|
|
1624 | (5) |
|
Response by Histologic Subtype and Site |
|
|
1629 | (2) |
|
Recommendations for Patients with Advanced Disease |
|
|
1631 | (1) |
|
|
|
1631 | (7) |
|
|
|
1638 | (49) |
|
|
|
|
|
|
|
Classification and Types of Bone Tumor |
|
|
1638 | (1) |
|
Radiographic Evaluation and Diagnosis |
|
|
1639 | (1) |
|
|
|
1640 | (1) |
|
|
|
1641 | (1) |
|
|
|
1642 | (2) |
|
Biopsy Technique and Timing |
|
|
1644 | (1) |
|
Restaging after Induction (Preoperative) Chemotherapy |
|
|
1645 | (1) |
|
Surgical Management of Skeletal Tumors |
|
|
1646 | (1) |
|
Principles and Techniques of Limb-Sparing Surgery |
|
|
1647 | (1) |
|
Limb-Sparing Surgery and Perioperative Pain Management |
|
|
1648 | (4) |
|
|
|
1652 | (1) |
|
|
|
1652 | (1) |
|
Chemotherapy for Bone Sarcomas |
|
|
1652 | (6) |
|
Radiotherapy for Bone Tumors |
|
|
1658 | (2) |
|
|
|
1660 | (27) |
|
Benign and Maliganant Mesothelioma |
|
|
1687 | (30) |
|
|
|
|
|
|
|
|
|
Mechanism of Asbestos-Induced Oncogenesis |
|
|
1687 | (1) |
|
Mechanism of Asbestos Pathogenicity |
|
|
1688 | (1) |
|
Overview of Molecular Mechanisms in Mesothelioma |
|
|
1688 | (2) |
|
|
|
1690 | (1) |
|
Radiation and Mesothelioma |
|
|
1690 | (1) |
|
Genetic Predisposition to Mesothelioma |
|
|
1690 | (1) |
|
Pathology of Mesothelioma |
|
|
1691 | (2) |
|
Solitary Fibrous Tumors of Pleura |
|
|
1693 | (1) |
|
Clinical Presentations of Malignant Pleural Mesothelioma |
|
|
1693 | (5) |
|
|
|
1698 | (1) |
|
|
|
1699 | (1) |
|
|
|
1699 | (1) |
|
|
|
1700 | (1) |
|
|
|
1700 | (10) |
|
Malignant Peritoneal Mesothelioma |
|
|
1710 | (2) |
|
Malignant Mesothelioma of the Tunica Vaginalis Testis |
|
|
1712 | (1) |
|
Malignant Mesothelioma of the Pericardium |
|
|
1712 | (5) |
|
|
|
1717 | (28) |
|
|
|
|
|
|
|
1717 | (1) |
|
General Approach to Management of Skin Cancer |
|
|
1718 | (5) |
|
|
|
1723 | (18) |
|
Carcinoma Metastatic to Skin |
|
|
1741 | (1) |
|
|
|
1741 | (4) |
|
|
|
1745 | (82) |
|
Molecular Biology of Cutaneous Melanoma |
|
|
1745 | (9) |
|
|
|
|
|
|
|
1745 | (1) |
|
|
|
1746 | (3) |
|
Biologic Basis of Melanoma Development and Progression |
|
|
1749 | (5) |
|
|
|
1754 | (55) |
|
|
|
|
|
|
|
|
|
1754 | (1) |
|
|
|
1755 | (1) |
|
|
|
1756 | (1) |
|
|
|
1757 | (2) |
|
|
|
1759 | (1) |
|
|
|
1760 | (5) |
|
New Staging System for Melanoma |
|
|
1765 | (4) |
|
|
|
1769 | (1) |
|
Surgical Treatment of Primary Melanoma (Stages I to III) |
|
|
1769 | (5) |
|
|
|
1774 | (1) |
|
Management of Regional Nodes---Lymphadenectomy (Stage III) |
|
|
1774 | (4) |
|
Radiotherapy for Regional Metastases (Stage III) |
|
|
1778 | (1) |
|
|
|
1779 | (1) |
|
Adjuvant Systemic Therapy (Stages II and III) |
|
|
1780 | (6) |
|
Follow-Up of Melanoma Patients (Stages I to III) |
|
|
1786 | (1) |
|
Diagnosis of Stage IV Melanoma |
|
|
1786 | (1) |
|
Surgery and Irradiation for Distant Metastases (Stage IV) |
|
|
1787 | (5) |
|
Systemic Treatment of Stage IV Melanoma |
|
|
1792 | (17) |
|
|
|
1809 | (18) |
|
|
|
|
|
|
|
|
|
|
|
1809 | (1) |
|
|
|
1810 | (1) |
|
|
|
1810 | (1) |
|
Etiology and Pathogenesis |
|
|
1811 | (1) |
|
|
|
1812 | (1) |
|
|
|
1813 | (2) |
|
|
|
1815 | (1) |
|
|
|
1816 | (1) |
|
|
|
1817 | (6) |
|
|
|
1823 | (1) |
|
|
|
1824 | (3) |
|
Neoplasms of the Central Nervous System |
|
|
1827 | (62) |
|
Molecular Biology of Central Nervous System Neoplasms |
|
|
1827 | (7) |
|
|
|
|
|
Diffuse, Fibrillary Astrocytomas |
|
|
1827 | (2) |
|
|
|
1829 | (2) |
|
|
|
1831 | (1) |
|
|
|
1831 | (1) |
|
|
|
1832 | (1) |
|
|
|
1832 | (1) |
|
Neurologic Tumor Syndromes |
|
|
1832 | (1) |
|
|
|
1833 | (1) |
|
Neoplasms of the Central Nervous System |
|
|
1834 | (55) |
|
|
|
|
|
|
|
|
|
|
|
1834 | (2) |
|
Anatomic and Clinical Considerations |
|
|
1836 | (2) |
|
|
|
1838 | (3) |
|
|
|
1841 | (2) |
|
|
|
1843 | (2) |
|
|
|
1845 | (2) |
|
|
|
1847 | (7) |
|
|
|
1854 | (2) |
|
|
|
1856 | (1) |
|
Optic, Chiasmal, and Hypothalamic Gliomas |
|
|
1856 | (2) |
|
|
|
1858 | (2) |
|
|
|
1860 | (2) |
|
|
|
1862 | (3) |
|
Primitive Neuroepithelial Tumors |
|
|
1865 | (1) |
|
|
|
1865 | (4) |
|
|
|
1869 | (2) |
|
|
|
1871 | (2) |
|
|
|
1873 | (1) |
|
Acoustic Neuromas (Vestibular Schwannomas) |
|
|
1874 | (1) |
|
|
|
1875 | (1) |
|
Chordomas and Chondrosarcomas |
|
|
1876 | (1) |
|
|
|
1877 | (2) |
|
Choroid Plexus Papillomas and Carcinomas |
|
|
1879 | (1) |
|
|
|
1880 | (9) |
|
|
|
1889 | (50) |
|
Molecular Biology of Childhood Cancers |
|
|
1889 | (9) |
|
|
|
|
|
|
|
1890 | (1) |
|
Retinoblastoma: The Paradigm |
|
|
1890 | (1) |
|
Wilms' Tumor: Three Distinct Loci |
|
|
1891 | (1) |
|
|
|
1892 | (1) |
|
|
|
1892 | (1) |
|
Ewing's Sarcoma Family of Tumors |
|
|
1893 | (1) |
|
|
|
1893 | (1) |
|
Hereditary Syndromes Associated with Tumors of Childhood |
|
|
1894 | (1) |
|
Predictive Testing for Germline Mutations and Childhood Cancers |
|
|
1895 | (1) |
|
|
|
1895 | (3) |
|
Solid Tumors of Childhood |
|
|
1898 | (41) |
|
|
|
|
|
|
|
|
|
|
|
1898 | (1) |
|
Management of Childhood Cancer |
|
|
1898 | (1) |
|
|
|
1898 | (5) |
|
Favorable Histology Wilms' Tumor |
|
|
1903 | (1) |
|
|
|
1904 | (5) |
|
|
|
1909 | (2) |
|
Advanced Unilateral Disease |
|
|
1911 | (1) |
|
Limited Unilateral or Limited Bilateral Disease |
|
|
1911 | (1) |
|
|
|
1911 | (1) |
|
|
|
1912 | (1) |
|
|
|
1912 | (7) |
|
Ewing's Sarcoma and Peripheral Primitive Neuroectodermal Tumor |
|
|
1919 | (4) |
|
|
|
1923 | (3) |
|
|
|
1926 | (2) |
|
Clinical Presentation and Treatment by Anatomic Site |
|
|
1928 | (11) |
|
|
|
1939 | (138) |
|
Leukemias and Lymphomas of Childhood |
|
|
1939 | (18) |
|
|
|
|
|
|
|
1939 | (9) |
|
|
|
1948 | (5) |
|
|
|
1953 | (4) |
|
|
|
1957 | (41) |
|
|
|
|
|
|
|
|
|
|
|
1957 | (1) |
|
|
|
1958 | (1) |
|
Biologic Background for Classification of Lymphoid Neoplasms |
|
|
1959 | (8) |
|
Principles of the Revised European-American Classification of Lymphoid Neoplasms' World Health Organization Classification of Lymphoid Neoplasms |
|
|
1967 | (2) |
|
Principles of Management of Non-Hodgkin's Lymphoma |
|
|
1969 | (2) |
|
Specific Disease Entities |
|
|
1971 | (19) |
|
Special Clinical Situations |
|
|
1990 | (8) |
|
Cutaneous T-Cell Lymphomas |
|
|
1998 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
1998 | (1) |
|
|
|
1998 | (1) |
|
|
|
1998 | (1) |
|
|
|
1999 | (1) |
|
Approach to the Patient with Mycosis Fungoides |
|
|
2000 | (2) |
|
|
|
2002 | (1) |
|
|
|
2003 | (7) |
|
Other Clinical Management Issues |
|
|
2010 | (2) |
|
Primary Central Nervous System Lymphoma |
|
|
2012 | (8) |
|
|
|
|
|
|
|
2012 | (1) |
|
|
|
2013 | (1) |
|
|
|
2013 | (1) |
|
|
|
2014 | (1) |
|
Immunologically Normal Patients |
|
|
2015 | (4) |
|
Immunocompromised Patients |
|
|
2019 | (1) |
|
|
|
2020 | (57) |
|
|
|
|
|
|
|
|
|
2020 | (1) |
|
Etiology and Epidemiology |
|
|
2021 | (1) |
|
Biology and Cell of Origin |
|
|
2021 | (5) |
|
|
|
2026 | (6) |
|
|
|
2032 | (2) |
|
|
|
2034 | (1) |
|
|
|
2035 | (3) |
|
|
|
2038 | (21) |
|
|
|
2059 | (3) |
|
|
|
2062 | (2) |
|
|
|
2064 | (1) |
|
New Drugs for Treatment of Hodgkin's Lymphoma |
|
|
2064 | (1) |
|
|
|
2065 | (3) |
|
|
|
2068 | (9) |
|
|
|
2077 | (44) |
|
Molecular Biology of Acute Leukemias |
|
|
2077 | (11) |
|
|
|
|
|
|
|
2077 | (1) |
|
Recurring Chromosomal Abnormalities in Acute Leukemia |
|
|
2078 | (5) |
|
Deletions and Numeric Abnormalities in Acute Leukemias |
|
|
2083 | (1) |
|
Chromosomal Translocations That Result in Overexpression of Otherwise Normal Genes |
|
|
2084 | (1) |
|
Point Mutations in Acute Leukemia |
|
|
2084 | (1) |
|
Mutational Complementation Groups in Acute Leukemias |
|
|
2085 | (1) |
|
|
|
2086 | (2) |
|
Management of Acute Leukemias |
|
|
2088 | (33) |
|
|
|
|
|
|
|
Epidemiology and Etiology |
|
|
2088 | (2) |
|
Biology of Acute Leukemias |
|
|
2090 | (1) |
|
Diagnosis and Classification of Acute Leukemias |
|
|
2091 | (7) |
|
Principles of Clinical Management of Acute Myelogenous Leukemia |
|
|
2098 | (2) |
|
Treatment of Newly Diagnosed Acute Myelogenous Leukemia |
|
|
2100 | (1) |
|
|
|
2100 | (6) |
|
Treatment of Relapsed Acute Myelogenous Leukemia |
|
|
2106 | (9) |
|
|
|
2115 | (6) |
|
|
|
2121 | (34) |
|
Chronic Myelogenous Leukemia |
|
|
2121 | (12) |
|
|
|
|
|
|
|
2121 | (1) |
|
|
|
2121 | (2) |
|
Diagnosis and Clinical Course |
|
|
2123 | (1) |
|
Treatment of Chronic-Phase Disease |
|
|
2124 | (6) |
|
|
|
2130 | (1) |
|
|
|
2131 | (2) |
|
Chronic Lymphoid Leukemias |
|
|
2133 | (11) |
|
|
|
|
|
|
|
2133 | (2) |
|
|
|
2135 | (1) |
|
|
|
2135 | (1) |
|
|
|
2135 | (3) |
|
Treatment and Response Criteria |
|
|
2138 | (2) |
|
|
|
2140 | (1) |
|
Second Malignancies and Transformation |
|
|
2141 | (1) |
|
|
|
2142 | (1) |
|
Large Granular Lymphocyte Leukemia |
|
|
2142 | (1) |
|
|
|
2142 | (2) |
|
Myelodysplastic Syndromes |
|
|
2144 | (11) |
|
|
|
|
|
Incidence and Epidemiology |
|
|
2144 | (1) |
|
|
|
2144 | (1) |
|
Classification and Prognostic Factors |
|
|
2145 | (1) |
|
Biology and Pathophysiology of Myelodysplastic Syndromes |
|
|
2146 | (2) |
|
|
|
2148 | (1) |
|
|
|
2148 | (1) |
|
|
|
2148 | (1) |
|
Subtypes of Myelodysplastic Syndromes |
|
|
2148 | (1) |
|
Therapy of Myelodysplastic Syndromes |
|
|
2149 | (4) |
|
|
|
2153 | (2) |
|
|
|
2155 | (34) |
|
|
|
|
|
|
|
2155 | (1) |
|
|
|
2156 | (1) |
|
Etiology: Environmental Exposure |
|
|
2156 | (1) |
|
|
|
2157 | (6) |
|
|
|
2163 | (2) |
|
|
|
2165 | (3) |
|
|
|
2168 | (2) |
|
|
|
2170 | (2) |
|
|
|
2172 | (9) |
|
Waldenstrom's Macroglobulinemia |
|
|
2181 | (8) |
|
|
|
2189 | (24) |
|
|
|
|
|
|
|
Endocrinologic Manifestations of Cancer |
|
|
2189 | (4) |
|
Hematologic Manifestations of Cancer |
|
|
2193 | (3) |
|
Gastrointestinal Manifestations of Cancer |
|
|
2196 | (1) |
|
Renal Manifestations of Nonrenal Cancer |
|
|
2197 | (1) |
|
Cutaneous Manifestations of Cancer |
|
|
2197 | (3) |
|
Neurologic Manifestations of Cancer |
|
|
2200 | (7) |
|
Miscellaneous Paraneoplastic Syndromes |
|
|
2207 | (6) |
|
Cancer of Unknown Primary Site |
|
|
2213 | (24) |
|
|
|
|
|
Poorly Differentiated Neoplasms of Unknown Primary Site |
|
|
2214 | (2) |
|
Poorly Differentiated Carcinoma (with or without Features of Adenocarcinoma) of Unknown Primary Site |
|
|
2216 | (5) |
|
Neuroendocrine Carcinoma of Unknown Primary Site |
|
|
2221 | (1) |
|
Adenocarcinoma of Unknown Primary Site |
|
|
2222 | (3) |
|
Squamous Carcinoma of Unknown Primary Site |
|
|
2225 | (1) |
|
Chemotherapy for Metastatic Carcinoma of Unknown Primary Site |
|
|
2226 | (3) |
|
Special Issues in Carcinoma of Unknown Primary Site |
|
|
2229 | (3) |
|
|
|
2232 | (5) |
|
Peritoneal Carcinomalosis |
|
|
2237 | (10) |
|
|
|
|
|
2237 | (1) |
|
|
|
2238 | (1) |
|
|
|
2238 | (4) |
|
|
|
2242 | (5) |
|
Immunosuppression-Related Malignancies |
|
|
2247 | (26) |
|
AIDS-Related Malignancies |
|
|
2247 | (16) |
|
|
|
|
|
|
|
2247 | (6) |
|
AIDS-Associated Lymphomas |
|
|
2253 | (5) |
|
Primary Central Nervous System Lymphoma in AIDS |
|
|
2258 | (1) |
|
|
|
2259 | (1) |
|
Anogenital Cancers in Human Immunodeficiency Virus Infection |
|
|
2259 | (1) |
|
|
|
2260 | (3) |
|
Transplantation-Related Malignancies |
|
|
2263 | (10) |
|
|
|
Immune Surveillance and Tumor Development |
|
|
2263 | (1) |
|
Hematopoietic Stem Cell Transplant Recipients |
|
|
2263 | (4) |
|
Organ Transplant Recipients |
|
|
2267 | (6) |
|
|
|
2273 | (36) |
|
Superior Vena Cava Syndrome |
|
|
2273 | (8) |
|
|
|
Anatomy and Pathophysiology |
|
|
2273 | (1) |
|
Etiology and Natural History |
|
|
2273 | (2) |
|
|
|
2275 | (1) |
|
|
|
2276 | (1) |
|
|
|
2277 | (2) |
|
|
|
2279 | (2) |
|
Increased Intracranial Pressure |
|
|
2281 | (6) |
|
|
|
Pathophysiologic Considerations |
|
|
2281 | (1) |
|
Epidemiology and Pathogenesis |
|
|
2281 | (1) |
|
|
|
2282 | (2) |
|
|
|
2284 | (2) |
|
|
|
2286 | (1) |
|
|
|
2287 | (5) |
|
|
|
|
|
2287 | (1) |
|
|
|
2287 | (2) |
|
|
|
2289 | (1) |
|
|
|
2290 | (1) |
|
|
|
2290 | (1) |
|
|
|
2291 | (1) |
|
|
|
2291 | (1) |
|
|
|
2292 | (1) |
|
|
|
2292 | (9) |
|
|
|
|
|
2292 | (2) |
|
|
|
2294 | (1) |
|
|
|
2295 | (1) |
|
Lactic Acidosis and Cancer |
|
|
2296 | (1) |
|
|
|
2297 | (2) |
|
Cancer-Related Hemolytic-Uremic Syndrome |
|
|
2299 | (2) |
|
|
|
2301 | (8) |
|
|
|
|
|
|
|
2301 | (1) |
|
|
|
2301 | (3) |
|
|
|
2304 | (1) |
|
|
|
2305 | (2) |
|
|
|
2307 | (1) |
|
|
|
2307 | (2) |
|
Specialized Techniques in Cancer Management |
|
|
2309 | (14) |
|
Vascular Access and Specialized Techniques of Drug Delivery |
|
|
2309 | (7) |
|
|
|
|
|
2309 | (3) |
|
|
|
2312 | (1) |
|
|
|
2312 | (2) |
|
Catheter-Related Complications |
|
|
2314 | (2) |
|
|
|
2316 | (7) |
|
H. Richard Alexander, Jr. |
|
|
Principles of Isolation Perfusion |
|
|
2316 | (2) |
|
Results of Isolation Perfusion |
|
|
2318 | (1) |
|
Current Status of Isolated Limb Perfusion |
|
|
2319 | (2) |
|
Current Status of Isolated Hepatic Perfusion |
|
|
2321 | (1) |
|
Status of Isolation Perfusion of Others Sites |
|
|
2321 | (1) |
|
Variations of Isolation Perfusion Techniques |
|
|
2321 | (1) |
|
|
|
2321 | (2) |
|
Treatment of Metastatic Cancer |
|
|
2323 | (76) |
|
|
|
2323 | (14) |
|
|
|
|
|
|
|
|
|
2323 | (10) |
|
|
|
2333 | (4) |
|
Metastatic Cancer to the Lung |
|
|
2337 | (15) |
|
|
|
|
|
|
|
2337 | (1) |
|
|
|
2337 | (2) |
|
|
|
2339 | (7) |
|
|
|
2346 | (6) |
|
Metastatic Cancer to the Liver |
|
|
2352 | (16) |
|
H. Richard Alexander, Jr. |
|
|
|
|
|
|
Natural History of Liver Metastases |
|
|
2353 | (1) |
|
Imaging of Hepatic Metastases |
|
|
2354 | (1) |
|
Resection: Technical Considerations |
|
|
2354 | (1) |
|
Results of Hepatic Resection for Colorectal Cancer |
|
|
2355 | (1) |
|
Results of Resection for Noncolorectal Cancers |
|
|
2355 | (1) |
|
Hepatic Arterial Chemotherapy |
|
|
2356 | (2) |
|
Toxicity of Hepatic Arterial Infusion Therapy with Floxuridine |
|
|
2358 | (1) |
|
Other Agents Used with Hepatic Arterial Infusion |
|
|
2359 | (1) |
|
Adjuvant Therapy after Resection of Colorectal Liver Metastases |
|
|
2359 | (1) |
|
|
|
2360 | (1) |
|
|
|
2360 | (1) |
|
Hepatic Artery Infusion with Hepatic Venous Filtration |
|
|
2360 | (1) |
|
Isolated Hepatic Perfusion |
|
|
2361 | (1) |
|
Chemoembolization for Metastatic Cancer to the Liver |
|
|
2361 | (1) |
|
|
|
2362 | (1) |
|
|
|
2363 | (1) |
|
|
|
2363 | (1) |
|
Other Ablative Techniques |
|
|
2364 | (1) |
|
Results of Whole Liver Irradiation ± Chemotherapy |
|
|
2365 | (1) |
|
|
|
2366 | (2) |
|
Metastatic Cancer to the Bone |
|
|
2368 | (13) |
|
|
|
|
|
|
|
2368 | (1) |
|
|
|
2369 | (1) |
|
|
|
2369 | (1) |
|
|
|
2370 | (1) |
|
|
|
2371 | (1) |
|
|
|
2371 | (10) |
|
Malignant Pleural and Pericardial Effusions |
|
|
2381 | (11) |
|
|
|
|
|
Malignant Pleural Effusion |
|
|
2381 | (6) |
|
Malignant Pericardial Effusion |
|
|
2387 | (5) |
|
|
|
2392 | (7) |
|
|
|
|
|
Douglas J. Schwartzentruber |
|
|
|
|
2392 | (1) |
|
Treatment of Malignant Ascites |
|
|
2393 | (3) |
|
|
|
2396 | (3) |
|
|
|
2399 | (62) |
|
|
|
2399 | (15) |
|
|
|
|
|
|
|
|
|
2400 | (6) |
|
Transfusion Reactions and Complications |
|
|
2406 | (3) |
|
Transfusion-Transmitted Disease |
|
|
2409 | (1) |
|
Use of Special Blood Products in Oncology Patients |
|
|
2410 | (1) |
|
|
|
2411 | (1) |
|
Effect of Growth Factors on Transfusion Medicine |
|
|
2412 | (1) |
|
|
|
2412 | (2) |
|
Autologous Stem Cell Transplantation |
|
|
2414 | (9) |
|
|
|
|
|
|
|
2415 | (1) |
|
|
|
2415 | (1) |
|
Inadequate Mobilization of Stem Cells |
|
|
2416 | (2) |
|
|
|
2418 | (1) |
|
Practical Considerations for the Potential Autologous Stem Cell Patient |
|
|
2419 | (1) |
|
High-Dose Therapy Regimens: New Directions |
|
|
2419 | (2) |
|
Late Toxicity: Myelodysplasia and Secondary Leukemia |
|
|
2421 | (1) |
|
|
|
2421 | (2) |
|
Allogeneic Hematopoietic Stem Cell Transplantation |
|
|
2423 | (19) |
|
|
|
|
|
2424 | (1) |
|
Graft-Versus-Leukemia Effect |
|
|
2425 | (2) |
|
Mechanisms of Graft-Versus-Leukemia Effect |
|
|
2427 | (1) |
|
Complications of Allogeneic Hematopoietic Stem Cell Transplantation |
|
|
2427 | (2) |
|
Epstein-Barr Virus Lymphoproliferative Disorder |
|
|
2429 | (3) |
|
Sources of Allogeneic Hematopoietic Stem Cells |
|
|
2432 | (2) |
|
Results of Conventional Allogeneic Transplantation for Hematologic Malignancies |
|
|
2434 | (1) |
|
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation |
|
|
2435 | (4) |
|
|
|
2439 | (3) |
|
Hematopoietic Growth Factors |
|
|
2442 | (19) |
|
|
|
|
|
Overview of Hematopoiesis and Hematopoietic Growth Factors |
|
|
2442 | (6) |
|
Clinical Use of Recombinant Erythropoietin in Cancer Therapy |
|
|
2448 | (2) |
|
Anemia Related to Myeloproliferative Disorders |
|
|
2450 | (1) |
|
Predictors of Recombinant Erythropoietin Therapy Response |
|
|
2451 | (1) |
|
Clinical Use of Recombinant Granulocyte Colony-Stimulating Factors in Cancer Therapy |
|
|
2452 | (3) |
|
Clinical Use of Recombinant Interleukin-11 in Cancer Therapy |
|
|
2455 | (1) |
|
Hematopoietic Growth Factors in Development |
|
|
2456 | (1) |
|
|
|
2456 | (5) |
|
Infections in the Cancer Patient |
|
|
2461 | (54) |
|
|
|
|
|
|
|
|
|
Factors Predisposing Cancer Patients to Infection |
|
|
2461 | (4) |
|
Bacterial Infections in Cancer Patients |
|
|
2465 | (4) |
|
|
|
2469 | (8) |
|
|
|
2477 | (7) |
|
|
|
2484 | (2) |
|
|
|
2486 | (10) |
|
|
|
2496 | (10) |
|
Immune Augmentation Strategies |
|
|
2506 | (9) |
|
Adverse Effects of Treatment |
|
|
2515 | (100) |
|
|
|
2515 | (8) |
|
|
|
|
|
|
|
2515 | (1) |
|
Pathophysiology of Nausea and Vomiting |
|
|
2515 | (2) |
|
|
|
2517 | (1) |
|
Control of Emesis and Risk Factors |
|
|
2518 | (1) |
|
|
|
2519 | (1) |
|
Treatment Options Based on Emesis Category |
|
|
2520 | (1) |
|
|
|
2520 | (1) |
|
Radiation-Induced Nausea and Vomiting |
|
|
2521 | (1) |
|
Nausea and Vomiting Secondary to Comorbid Conditions |
|
|
2522 | (1) |
|
Improving Antiemetic Control |
|
|
2522 | (1) |
|
|
|
2523 | (12) |
|
|
|
|
|
|
|
2523 | (2) |
|
Sequelae of Oral Complications |
|
|
2525 | (1) |
|
Strategies for Prevention and Treatment of Oral Complications |
|
|
2526 | (7) |
|
Future Research Directions |
|
|
2533 | (1) |
|
|
|
2533 | (2) |
|
|
|
2535 | (10) |
|
|
|
|
|
Radiation-Induced Pulmonary Toxicity |
|
|
2535 | (3) |
|
Radiation-Related Bronchiolitis Obliterans with Organizing Pneumonia |
|
|
2538 | (1) |
|
Chemotherapy-Induced Pulmonary Toxicity |
|
|
2539 | (6) |
|
|
|
2545 | (11) |
|
|
|
|
|
|
|
2545 | (2) |
|
|
|
2547 | (1) |
|
|
|
2547 | (1) |
|
|
|
2547 | (1) |
|
|
|
2547 | (1) |
|
|
|
2548 | (1) |
|
|
|
2549 | (1) |
|
Radiation-Induced Heart Disease |
|
|
2549 | (4) |
|
|
|
2553 | (3) |
|
|
|
2556 | (4) |
|
|
|
|
|
|
|
2556 | (1) |
|
|
|
2556 | (1) |
|
|
|
2557 | (1) |
|
|
|
2557 | (1) |
|
|
|
2557 | (2) |
|
|
|
2559 | (1) |
|
|
|
2560 | (15) |
|
|
|
Rena Vassilopoulou-Sellin |
|
|
|
|
Effects of Cytotoxic Agents on Adult Men |
|
|
2560 | (3) |
|
Effects of Cytotoxic Agents on Adult Women |
|
|
2563 | (3) |
|
Effects of Cytotoxic Agents on Children |
|
|
2566 | (1) |
|
Gonadal Dysfunction after Cranial Irradiation |
|
|
2566 | (1) |
|
Preservation of Fertility, Hormone Levels, and Sexual Function |
|
|
2567 | (3) |
|
Prevention and Management of Erectile and Ejaculatory Dysfunction |
|
|
2570 | (1) |
|
|
|
2571 | (1) |
|
|
|
2572 | (3) |
|
|
|
2575 | (27) |
|
|
|
|
|
Methods to Assess Second Cancer Risk |
|
|
2575 | (1) |
|
Carcinogenicity of Individual Treatment Modalities |
|
|
2576 | (4) |
|
Risk of Second Malignancy in Patients with Selected Primary Cancers |
|
|
2580 | (18) |
|
|
|
2598 | (4) |
|
|
|
2602 | (13) |
|
|
|
|
|
2603 | (4) |
|
|
|
2607 | (3) |
|
|
|
2610 | (1) |
|
Hypersensitivity Reactions |
|
|
2611 | (1) |
|
|
|
2612 | (3) |
|
Supportive Care and Quality of Life |
|
|
2615 | (104) |
|
Management of Cancer Pain |
|
|
2615 | (34) |
|
|
|
|
|
2615 | (1) |
|
Barriers to Cancer Pain Management |
|
|
2616 | (1) |
|
|
|
2617 | (1) |
|
Anatomy and Physiology of Pain |
|
|
2617 | (1) |
|
|
|
2618 | (1) |
|
|
|
2619 | (1) |
|
|
|
2619 | (1) |
|
|
|
2619 | (2) |
|
Classification of Patients with Cancer Pain |
|
|
2621 | (3) |
|
|
|
2624 | (1) |
|
Clinical Assessment of Pain |
|
|
2624 | (3) |
|
Management of Cancer Pain |
|
|
2627 | (1) |
|
|
|
2627 | (3) |
|
|
|
2630 | (9) |
|
|
|
2639 | (1) |
|
Anesthetic and Neurosurgical Approaches |
|
|
2639 | (6) |
|
|
|
2645 | (1) |
|
Sedation in the Imminently Dying |
|
|
2645 | (1) |
|
Algorithm for Cancer Pain Management |
|
|
2646 | (1) |
|
|
|
2646 | (3) |
|
|
|
2649 | (13) |
|
|
|
|
|
|
|
|
|
2649 | (1) |
|
Weight Loss and Cancer Cachexia |
|
|
2650 | (1) |
|
Nutrition Support for Weight Loss and Cancer Cachexia |
|
|
2651 | (1) |
|
Nutrition and Tumor Growth |
|
|
2651 | (1) |
|
Nutritional Assessment of the Cancer Patient |
|
|
2652 | (1) |
|
Indications for Nutrition Support |
|
|
2652 | (1) |
|
Parenteral versus Enteral Nutrition in Cancer Patients |
|
|
2652 | (1) |
|
Specific Indications for the Use of Total Parenteral Nutrition in the Cancer Patient |
|
|
2653 | (5) |
|
Improving the Efficacy of Current Feeding Regimens |
|
|
2658 | (1) |
|
Techniques of Providing Nutritional Support |
|
|
2659 | (2) |
|
|
|
2661 | (1) |
|
|
|
2662 | (14) |
|
|
|
|
|
|
|
Sexual Health and Physiology |
|
|
2662 | (1) |
|
Sexual Problems and Their Prevalence among the General Population |
|
|
2663 | (1) |
|
Impact of Cancer and Its Treatment on Sexual Health |
|
|
2664 | (1) |
|
|
|
2665 | (3) |
|
Sexual Problems Associated with Specific Cancers |
|
|
2668 | (3) |
|
Strategies for Assessment and Intervention |
|
|
2671 | (2) |
|
|
|
2673 | (3) |
|
|
|
2676 | (7) |
|
|
|
Why Is Cancer Genetic Counseling Necessary? |
|
|
2676 | (1) |
|
Who Is a Candidate for Cancer Genetic Counseling? |
|
|
2677 | (1) |
|
Components of the Cancer Genetic Counseling Session |
|
|
2677 | (3) |
|
Issues in Cancer Genetic Counseling |
|
|
2680 | (1) |
|
|
|
2681 | (2) |
|
|
|
2683 | (8) |
|
|
|
|
|
|
|
2683 | (2) |
|
Psychological Complications of Cancer |
|
|
2685 | (3) |
|
|
|
2688 | (3) |
|
|
|
2691 | (11) |
|
|
|
Initial Diagnosis of Cancer |
|
|
2691 | (1) |
|
|
|
2691 | (1) |
|
|
|
2691 | (2) |
|
|
|
2693 | (1) |
|
|
|
2693 | (1) |
|
|
|
2694 | (1) |
|
|
|
2694 | (1) |
|
Trends Affecting Demand for Community Services |
|
|
2695 | (1) |
|
|
|
2696 | (1) |
|
Appendix: Common Community Resources |
|
|
2696 | (6) |
|
Specialized Care of the Terminally III |
|
|
2702 | (17) |
|
|
|
|
|
2702 | (1) |
|
|
|
2703 | (1) |
|
|
|
2703 | (1) |
|
Barriers That Inhibit Advance Care Planning Discussions |
|
|
2704 | (1) |
|
|
|
2704 | (1) |
|
|
|
2704 | (1) |
|
|
|
2704 | (1) |
|
Cultural/Religious Considerations |
|
|
2705 | (1) |
|
Care without Chemotherapy |
|
|
2706 | (1) |
|
|
|
2706 | (1) |
|
|
|
2707 | (1) |
|
|
|
2708 | (6) |
|
|
|
2714 | (1) |
|
|
|
2715 | (1) |
|
|
|
2715 | (2) |
|
|
|
2717 | (2) |
|
Rehabilitation of the Cancer Patient |
|
|
2719 | (28) |
|
|
|
|
|
|
|
Impact of Cancer Treatment on Function |
|
|
2720 | (5) |
|
Rehabilitation Interventions |
|
|
2725 | (7) |
|
Rehabilitation Hospitalization and Basic Functional Independence |
|
|
2732 | (1) |
|
|
|
2733 | (1) |
|
Rehabilitation Treatments of Specific Tumors |
|
|
2734 | (13) |
|
Societal Issues in Oncology |
|
|
2747 | (48) |
|
|
|
2747 | (12) |
|
|
|
Ethical Issues in Clinical Care in Oncology |
|
|
2747 | (5) |
|
Ethical Issues in Cancer Clinical Trials |
|
|
2752 | (5) |
|
|
|
2757 | (2) |
|
|
|
2759 | (8) |
|
|
|
|
|
2759 | (1) |
|
Medicare Cost-Containment Efforts |
|
|
2759 | (1) |
|
Medicare Reimbursement for Cancer Services |
|
|
2760 | (1) |
|
Medicaid Cost-Containment Efforts |
|
|
2761 | (1) |
|
Insurance Industry Cost-Containment Efforts |
|
|
2761 | (1) |
|
|
|
2762 | (1) |
|
Physician Economic Issues |
|
|
2762 | (1) |
|
National Cancer Institute--Designated and University Cancer Centers Economic Issues |
|
|
2763 | (1) |
|
|
|
2763 | (1) |
|
|
|
2764 | (1) |
|
Complementary and Alternative Medicine |
|
|
2765 | (1) |
|
Standardization of Practice |
|
|
2765 | (1) |
|
Health Economics and the Economic Burden of Cancer |
|
|
2765 | (1) |
|
|
|
2766 | (1) |
|
|
|
2767 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
History of U.S. Food and Drug Administration Regulation of Drugs and Biologies |
|
|
2767 | (1) |
|
U.S. Food and Drug Administration Oversight of Clinical Trials for Drugs and Biologics |
|
|
2768 | (1) |
|
Basis for Cancer Drug Approval |
|
|
2769 | (4) |
|
Drug Safety Reporting and Evaluation |
|
|
2773 | (1) |
|
Access to Investigational Drugs |
|
|
2773 | (1) |
|
Biologic Drug Products: Special Considerations |
|
|
2773 | (1) |
|
Regulation of Devices for Cancer Treatment and Diagnosis |
|
|
2774 | (2) |
|
U.S. Food and Drug Administration Initiatives and Guidances Expediting Approval of Cancer Drugs, Biologics, and Devices |
|
|
2776 | (1) |
|
|
|
2777 | (5) |
|
|
|
|
|
|
|
Applications of Telemedicine |
|
|
2778 | (1) |
|
Telemedicine in Other Countries |
|
|
2779 | (1) |
|
Telemedicine in Oncology Care---Current Practices |
|
|
2779 | (1) |
|
|
|
2779 | (1) |
|
Telemedicine Impact on National Medical Policy |
|
|
2780 | (1) |
|
|
|
2780 | (1) |
|
|
|
2781 | (1) |
|
International Differences in Oncology |
|
|
2782 | (6) |
|
|
|
|
|
|
|
|
|
2782 | (1) |
|
Cancers and Mortality: Differences in the More Developed Countries |
|
|
2782 | (1) |
|
|
|
2783 | (1) |
|
Anticancer Drug Development throughout the World |
|
|
2784 | (1) |
|
|
|
2784 | (1) |
|
Cancer Treatment Strategy: European and United States Differences |
|
|
2784 | (1) |
|
Differences in Cancer Survival |
|
|
2784 | (1) |
|
Access to Cancer Care in Developed Nations |
|
|
2785 | (1) |
|
Training as an Oncologist |
|
|
2786 | (1) |
|
|
|
2786 | (1) |
|
``Truth Telling'': Differences between Nations |
|
|
2786 | (1) |
|
|
|
2787 | (1) |
|
|
|
2787 | (1) |
|
The National Cancer Program |
|
|
2788 | (7) |
|
|
|
National Cancer Institute as Steward of the National Cancer Program |
|
|
2789 | (1) |
|
Harnessing the Power of Molecular Epidemiology |
|
|
2789 | (1) |
|
Developing an Integrative Understanding of Cancer Biology |
|
|
2790 | (1) |
|
Providing Bioinformatics Infrastructure |
|
|
2790 | (1) |
|
Developing Prevention, Early Detection, and Prediction Approaches |
|
|
2790 | (1) |
|
Facilitating the Development of Cancer Interventions |
|
|
2791 | (1) |
|
Creating an Integrated Clinical Trials System |
|
|
2791 | (1) |
|
Overcoming Health Disparities |
|
|
2791 | (1) |
|
A Critical ``Enterprise-Wide'' Opportunity: Technology Development and Integration |
|
|
2792 | (1) |
|
Integrative Computational Biology and Bioinformatics |
|
|
2792 | (1) |
|
|
|
2792 | (1) |
|
Bioengineering and Advanced Prototyping |
|
|
2792 | (1) |
|
Development and Preclinical Testing of Prevention and Therapeutic Agents |
|
|
2792 | (1) |
|
Shared Research Resources |
|
|
2793 | (1) |
|
|
|
2793 | (2) |
|
Information Systems in Oncology |
|
|
2795 | (10) |
|
|
|
|
|
2796 | (3) |
|
Electronic Medical Records |
|
|
2799 | (3) |
|
|
|
2802 | (3) |
Other versions by this Author